ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

In Congress: NCI Defends Role of Advisor In Response To House Inquiry

September 19, 1997

ASCO Board Accepts Plan To Establish New Bethesda Headquarters, Hire Chief Officer

April 23, 1993

Mayo Clinic Study Finds Samarium May Expand Options For Osteosarcoma

February 22, 2002

Final Issue of ‘87

December 11, 1987

Abstracts From AACR Annual Meeting

May 28, 1976

Brown Disagrees With Staff, Subgroup On Dichlorvos, Says It Is a Carcinogen

September 2, 1977